

REVIEW OF DECISIONS

BOARD MEETING

29-30 September 2020, Virtual Meeting



Reach every child

www.gavi.org

Decision 1: Appointment of Board Chair

The Gavi Alliance Board:

- a) **Appointed** José Manuel Barroso as an Unaffiliated Board Member in the seat currently held by Ngozi Okonjo-Iweala effective 1 January 2021 and until 31 December 2022; and
- b) **Appointed** José Manuel Barroso as Chair of the Board with individual signatory authority effective 1 January 2021 and until 31 December 2022.

Decision 2: Recalibrating Gavi 5.0 in the light of COVID-19 and successful replenishment (1/2)

The Gavi Alliance Board:

- a) **Provided guidance** on the recalibration of programmatic priorities and how they reflect appropriate trade-offs in light of COVID-19 and the successful replenishment with further discussion at the upcoming meeting of the Programme and Policy Committee;
- b) **Endorsed** the need for additional resources to the HSS allocation to support the goals of the zero-dose agenda and asked the Secretariat to bring to the Programme and Policy Committee a detailed proposal on approach and resourcing for recommendation to the Board;
- c) **Approved** the carry-forward of an amount of US\$ 85 million in co-financing waivers and extend to 2021 the authority granted by the Board in May 2020 to waive 2020 co-financing obligations on a case-by-case basis upon request from a country;

Decision 2: Recalibrating Gavi 5.0 in the light of COVID-19 and successful replenishment (2/2)

- d) **Noted** that additional resources may be required in 2021-2025 for innovation, vaccine-preventable disease (VPD) surveillance, the strategic partnership with India, and fiduciary risk assurance and financial management capacity, and after further discussion by the Programme and Policy Committee will be brought back to the Board for decision in due course per guidance provided at the September 2020 Board meeting;
- e) **Noted** that to deliver on the recalibrated priorities an increase in Partners' Engagement Framework (PEF) spending may be required, and that the details of this request will be brought to the upcoming meetings; and
- f) **Noted** that additional Secretariat resources may be required in 2021-2025, to be confirmed by the ongoing Organisational Review, and would be brought back to the October 2020 Audit and Finance Committee and December 2020 Board meetings respectively.

Decision 3: COVAX Facility operationalisation and vaccine programme (1/4)

The Gavi Alliance Board:

- a) **Approved** the Interim Terms of Reference of the COVAX Shareholders Council attached as Annex B to Doc 03;
- b) **Approved** the Interim Terms of Reference of the COVAX AMC Engagement Group attached as Annex E to Doc 03;
- c) **Approved** the Interim Terms of Reference of the COVAX AMC Stakeholders Group attached as Annex F to Doc 03;
- d) **Approved** the Interim Terms of Reference of the COVAX Consensus Group attached as Annex G to Doc 03;

Decision 3: COVAX Facility operationalisation and vaccine programme (2/4)

- e) **Approved** the proposal for AMC92 economies to cost-share vaccines up to US\$ 1.60-US\$ 2 per dose, assuming a 2-dose regimen, towards the full cost of purchasing a dose of vaccine [bearing in mind that Gavi will exercise flexibility and work with economies on a case-by-case basis to adjust vaccine cost-sharing contributions as needed in the first instance until end 2021, and with the expectation of additional cost-sharing on vaccine delivery, with targeted Gavi support (see decision point g) to supplement additional resources to be mobilised]. This flexibility will help to ensure that cost-sharing for vaccines does not prevent or delay the introduction of the vaccine in any economy, and that economies do not reallocate existing budgets for other routine vaccines towards COVAX cost-sharing, which would undermine both Gavi core programming and broader objectives;
- f) **Noted** that if domestic financing including grants and loans from the MDBs is not forthcoming, given the severe effects of the pandemic, including on fiscal space, and the late stage in country budgeting cycles, the AMC92 economies may not be required to cost-share;

Decision 3: COVAX Facility operationalisation and vaccine programme (3/4)

With reference to the discussion on Doc 02 *Recalibrating programmatic priorities for Gavi 5.0 in light of COVID-19 and the successful replenishment: Financial implications*, at the Gavi Alliance Audit and Finance Committee:

- g) **Approved** the allocation of US\$ 150 million from core resources [for initial funding] to prepare AMC92 economies to deliver COVID-19 vaccines, focusing on urgent technical assistance and cold chain needs with priority for 56 Gavi-eligible economies and others on a case by case basis;
- h) **Requested** the Gavi Secretariat to present to the Board in December 2020 the proposed approach for Gavi COVAX AMC support for India for COVID-19 vaccines and delivery;

Decision 3: COVAX Facility operationalisation and vaccine programme (4/4)

- i) **Noted** the proposed approach to not invest in Ultra-Cold Chain (UCC) at this time, and the associated risks regarding access to COVID-19 vaccines; and
- j) **Noted** the risks and mitigation measures outlined related to the COVAX Facility and welcomed the AFC's continued engagement on this in advance of a plan being presented to the Board in December 2020.

Thank you



www.gavi.org